leadf
logo-loader
viewValiRx PLC
(
AIM:VAL
)

Commercial discussions for ValiRx's lead cancer drug progressing 'rapidly'

George Morris, chief operations officer of ValiRx Plc (LON:VAL), tells Proactive's Andrew Scott commercial discussions to take their lead drug VAL 401 into a Phase III trial are progressing rapidly.

He says by nature they're detailed and complex but he hopes they'll be completed shortly and he's looking to undertake the trial early next year.

''[There's] significant interest in all the relevant areas most definitely'', Morris adds.

He also updates on developments within the rest of the portfolio including VAL 201 which is still in a phase I/II trial  for patients affected by hormone- sensitive and hormone-resistant prostate cancer.

Quick facts: ValiRx PLC

Follow
AIM:VAL

Price: 26.25 GBX

Market Cap: £17.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma presents at European Society for Medical Oncology (ESMO) Congress

Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London on the same day as the company present research at the European Society for Medical Oncology (ESMO) Congress. The firm presented the data from the phase I trial of its RXC004 monotherapy study which is their lead drug candidate,...

7 hours, 41 minutes ago

2 min read